Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more
Wuhan Thalys Med Tech Co Ltd (603716) - Total Assets
Latest total assets as of September 2025: CN¥2.09 Billion CNY
Based on the latest financial reports, Wuhan Thalys Med Tech Co Ltd (603716) holds total assets worth CN¥2.09 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wuhan Thalys Med Tech Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Wuhan Thalys Med Tech Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Wuhan Thalys Med Tech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wuhan Thalys Med Tech Co Ltd's total assets of CN¥2.09 Billion consist of 73.8% current assets and 26.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.4% |
| Accounts Receivable | CN¥1.48 Billion | 52.3% |
| Inventory | CN¥326.16 Million | 11.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥33.00 Million | 1.2% |
| Goodwill | CN¥43.70 Million | 1.5% |
Asset Composition Trend (2011–2024)
This chart illustrates how Wuhan Thalys Med Tech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Thalys Med Tech Co Ltd's current assets represent 73.8% of total assets in 2024, a decrease from 79.6% in 2011.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2024, down from 20.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 52.3% of total assets.
Wuhan Thalys Med Tech Co Ltd Competitors by Total Assets
Key competitors of Wuhan Thalys Med Tech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.47 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Wuhan Thalys Med Tech Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Wuhan Thalys Med Tech Co Ltd generates 0.64x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Wuhan Thalys Med Tech Co Ltd is currently not profitable relative to its asset base.
Wuhan Thalys Med Tech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 1.66 | 2.11 |
| Quick Ratio | 1.16 | 1.43 | 1.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥376.67 Million | CN¥ 898.86 Million | CN¥ 1.54 Billion |
Wuhan Thalys Med Tech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wuhan Thalys Med Tech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.47 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -15.3% |
| Total Assets | CN¥2.83 Billion |
| Market Capitalization | $546.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Thalys Med Tech Co Ltd's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Wuhan Thalys Med Tech Co Ltd's assets decreased by 15.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Wuhan Thalys Med Tech Co Ltd (2011–2024)
The table below shows the annual total assets of Wuhan Thalys Med Tech Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.83 Billion | -15.31% |
| 2023-12-31 | CN¥3.34 Billion | -15.34% |
| 2022-12-31 | CN¥3.95 Billion | -8.06% |
| 2021-12-31 | CN¥4.29 Billion | +9.91% |
| 2020-12-31 | CN¥3.91 Billion | +29.91% |
| 2019-12-31 | CN¥3.01 Billion | +16.43% |
| 2018-12-31 | CN¥2.58 Billion | +64.57% |
| 2017-12-31 | CN¥1.57 Billion | +43.65% |
| 2016-12-31 | CN¥1.09 Billion | +64.71% |
| 2015-12-31 | CN¥663.27 Million | +23.38% |
| 2014-12-31 | CN¥537.57 Million | +22.79% |
| 2013-12-31 | CN¥437.79 Million | +12.60% |
| 2012-12-31 | CN¥388.80 Million | +23.76% |
| 2011-12-31 | CN¥314.16 Million | -- |